Major US indexes finished in the green on Wednesday, May 7, after a volatile session as investors reacted to updates from the ...

Operating profit / (loss): Operating profit was $10.6 million for the three months ended 31 March 2025, compared to ($48.4) ...

The IMPACT trial reinforces the need to check for antiphospholipid syndrome in women after they experience stillbirth and is ...

Interim Report January-March 2025, is as of today, available on the Company's website, FINANCIAL OVERVIEW FIRST QUARTER 2025* • Revenue amounted ...

Sanofi will halt the development of its oral tumour necrosis factor (TNF) inhibitor balinatunfib as a monotherapy after it failed to reach the primary endpoint in a Phase II trial. Preliminary results ...

TNF inhibitors used in JAK-pot registries included adalimumab, etanercept, infliximab (Remicade), certolizumab pegol (Cimzia), and golimumab (Simponi). Besides tofacitinib, JAK inhibitors included ...

Since Humira hit the market, other TNF inhibitors have also been approved including Johnson & Johnson’s Remicade (infliximab), Amgen’s Enbrel (etanercept) and UCB’s Cimzia (certolizumab pegol).

Vimpat is UCB’s second-biggest drug after TNF inhibitor Cimzia (certolizumab pegol) which is also due to lose patent protection by 2024 and contributed €622 million out of total sales of €2. ...

with UCB’s Cimzia (certolizumab) and AbbVie’s Humira (adalimumab). “We think we have a very efficacious product, we showed a very positive safety profile, we have two weeks administration ...

In addition, UCB has recently gained approval for certolizumab pegol (Cimzia) for the treatment of RA with a dosing regimen of administration once every 4 weeks (which amounts to one more dose per ...